Skip to content

RNTX RNTX Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Gilead Sciences logo
Gilead SciencesGILD
AbbVie logo
AbbVieABBV
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
LQD
Liquidia CorporationLQDA

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's deferred tax assets and other non-current assets?
RNTX (RNTX) reported deferred tax assets and other non-current assets of $1.01M in Q1 2026.
How has RNTX's deferred tax assets and other non-current assets changed year-over-year?
RNTX's deferred tax assets and other non-current assets increased by 31.2% year-over-year, from $766K to $1.01M.
What is the long-term trend for RNTX's deferred tax assets and other non-current assets?
Over 4 years (2021 to 2025), RNTX's deferred tax assets and other non-current assets has grown at a -46.3% compound annual growth rate (CAGR), from $24K to $2K.